# From years to days: St. Petersburg scientists use AI to speed up cancer drug discovery

> St. Petersburg researchers built a configurable AI platform that ranks drug candidates in days, not years. It unifies data and models with clear next steps teams can reuse.

- Type: AI news
- Page: https://completeaitraining.com/news/from-years-to-days-st-petersburg-scientists-use-ai-to-speed/
- Published: 2025-11-14
- Updated: 2025-11-14
- Author: Jeroen Erne
- Jobs: IT and development
- Reading time: 3 min

### AI from St. Petersburg labs is speeding up drug development - here's what engineering teams can take from it

At a press event tied to the Priority-2030 program (launched in 2021 and now covering 141 Russian universities), researchers from St. Petersburg shared how they're using AI as a practical tool for cross-industry problems-drug discovery included.

The core idea: build a configurable platform for multimodal data and deliver predictive and prescriptive analytics across domains. In their words, it's a "constructor" of solutions-assemble methods, validate them on real tasks, and ship them as a single product.

#### A configurable platform for multimodal analytics

SPbPU is developing a digital platform that unifies methods under one roof-ingest, model, evaluate, explain, and recommend. The emphasis is not just on forecasting what will happen, but also explaining why and what to do next.

- Single entry point for different data types (text, tabular, chemical structures, imaging, etc.).
- Model catalog that can be adapted per sector-industry, medicine, and beyond.
- Task-first validation: test on concrete problems, prove accuracy, then deliver as a packaged tool.
- Prescriptive analytics: tie model outputs to recommended actions and plausible interventions.

#### Drug discovery use case: from years to days

A team led by Aleksandr Timin (SPbPU) is applying this approach to oncology. They built a database of 100,000+ aminothiophene-based structures and use a pre-trained neural network to rank the most promising compounds for synthesis and preclinical testing.

What used to take years of trial-and-error now compresses to days of model-driven triage. The lab then synthesizes short-listed molecules and feeds results back into the system to sharpen future screens.

- Data curation: clean structures, standardize formats (e.g., SMILES), and attach assay labels where available.
- Model screening: run pre-trained models to score efficacy, toxicity, and selectivity proxies.
- Downstream filters: uncertainty estimates, diversity selection, synthetic feasibility, and cost constraints.
- Lab handoff: generate a compact, testable batch; close the loop with active learning after assays.

#### What this means for engineering teams

This is platform thinking applied to AI. Rather than one-off models, you build shared components-data adapters, evaluation harnesses, explainability, and decision layers-then retarget them across domains.

- Prioritize reproducibility: version datasets, features, models, and evaluation pipelines.
- Mix methods pragmatically: graph models for molecules, Transformers for sequences and text, gradient boosting for tabular baselines.
- Track business metrics, not just AUC: cycle time to candidate, lab throughput, and validation yield.
- Close the loop: route experimental results back to training for active learning and drift control.

#### Practical implementation notes

- Data layer: schema for multimodal assets, lineage, and consent/usage constraints.
- Feature store + embeddings: molecular fingerprints, graph embeddings, learned representations.
- Model ops: containerize, run batch and on-demand scoring, enforce CI on metrics and fairness checks.
- Explainability: per-sample rationales (substructures, fragments), confidence scores, counterfactuals when possible.

#### Validation, risk, and compliance

Clinical contexts raise the bar. Log decisions, justify thresholds, and plan for audits. Align with regulatory thinking early-documentation, traceability, and human oversight are not optional.

For context on regulator expectations, see the FDA's perspective on AI/ML in drug development: [FDA: AI/ML in Drug Development](https://www.fda.gov/drugs/science-and-research-drugs/artificial-intelligence-and-machine-learning-ai-ml-drug-development?ref=completeaitraining.com).

#### Why this approach is gaining traction

AI is shifting from experiment to routine tool because the feedback loops are shorter and the infrastructure is reusable. Prove accuracy on a real task, package it, and move to the next adjacent problem.

The St. Petersburg work shows how a single platform can support discovery workflows while remaining adaptable to other industries-without rebuilding the stack every time.

#### Next steps for developers

- Define your target decision: what gets prioritized, funded, or synthesized based on model output.
- Stand up a minimal pipeline: ingestion → baseline model → evaluation → report → human-in-the-loop.
- Add uncertainty + explainability before scaling to production.
- Integrate an active learning loop once you have lab or real-world feedback.

#### Level up your skills

If you're building similar systems-MLOps, LLM tooling, and data-centric workflows-ongoing practice matters. You can explore role-based learning tracks here: [AI courses by job](https://completeaitraining.com/courses-by-job/).

---

This is the Markdown form of https://completeaitraining.com/news/from-years-to-days-st-petersburg-scientists-use-ai-to-speed/. The whole site is mapped at https://completeaitraining.com/llms.txt.
